Australia’s NHMRC releases interim guidelines on puberty blockers for trans youth
Consensus Summary
Australia’s National Health and Medical Research Council (NHMRC) has released interim guidelines advising that puberty blockers can be conditionally used for trans and gender-diverse children under 18, following a year-long review of international evidence. The advice, released on Monday, is open for public consultation until 18 January and marks the first national clinical guidance on the contentious issue. Both the ABC and the Guardian report that the NHMRC’s recommendations are advisory, meaning state governments like Queensland and the Northern Territory—where puberty blockers have been banned or restricted in public hospitals—can choose whether to adopt them. The guidelines emphasize shared decision-making between patients, carers, and clinicians, with puberty blockers recommended for those with gender incongruence who have begun puberty, regardless of whether they experience distress (gender dysphoria).
The push for national guidelines follows a wave of restrictions on puberty blockers in Australia and abroad. Queensland became the first state to limit access in 2025, followed by the Northern Territory, while New Zealand also banned new prescriptions last year despite opposition from health professionals. The NHMRC’s review, commissioned by Health Minister Mark Butler in 2025, was partly a response to these state-level bans. The interim advice is based on 15 non-randomized studies, most with follow-ups of six months to two years, which the NHMRC describes as low-certainty evidence. Both outlets note that puberty blockers have been used since the 1980s to treat precocious puberty and since the 1990s in gender-affirming care, though their long-term effects remain debated. The full guidelines, expected in 2028, will address broader aspects of trans youth care, including gender-affirming hormones.
Key figures in the debate include Health Minister Mark Butler, who has urged states to consider the NHMRC’s advice closely, and Queensland’s government, which has extended its pause on puberty blockers until 2031 pending results from the UK’s PATHWAYS trial. The ABC reports that Queensland’s independent review by psychiatrist Ruth Vine found limited evidence on fertility impacts and reversible bone health effects, while the Guardian highlights the NHMRC’s rejection of the ‘wait and see’ model as potentially harmful to young people’s well-being. Both sources quote the NHMRC’s conditional recommendation, which acknowledges the low certainty of evidence but emphasizes the importance of individualized care. Minister Butler, as reported by the ABC, expressed confidence that all states would engage seriously with the guidelines, though he stopped short of predicting policy changes in Queensland or the Northern Territory.
While both articles agree on the core facts—such as the timing of state bans, the NHMRC’s review process, and the conditional nature of the advice—they differ in emphasis. The ABC focuses more on the legal and political dimensions, including Queensland’s extension of its ban and the New Zealand High Court’s recent ruling overturning its ban. It also details the PATHWAYS trial’s delays and the NHMRC’s findings on bone health and fertility. The Guardian, meanwhile, underscores the ethical and clinical framing of the guidelines, particularly the NHMRC’s rejection of withholding care and its alignment with existing AusPATH standards. The Guardian also provides more context on the ‘wait and see’ model and the broader health disparities faced by trans youth, framing the guidelines as a step toward equity in healthcare.
Unresolved questions remain about how states will respond to the NHMRC’s advice. The ABC notes that Queensland and the Northern Territory have not indicated they will lift their bans, while the Guardian suggests the interim guidelines could pressure them to reconsider. Both outlets highlight the lack of high-certainty evidence due to ethical and practical limitations in researching pediatric treatments, particularly the challenges of conducting randomized controlled trials. The public consultation period, open until 18 January, will allow stakeholders to weigh in before the full guidelines are finalized in 2028. For now, the debate over puberty blockers continues, with advocates arguing for access and critics calling for greater caution in the absence of definitive long-term data.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- The NHMRC interim advice on puberty blockers was released on Monday for public consultation
- The NHMRC review included 15 non-randomised studies, most with follow-up of six months to two years
- The New Zealand government introduced a ban on new prescriptions of puberty blockers for children with gender dysphoria last year
- Queensland became the first state in Australia to restrict access to puberty blockers for children with gender dysphoria who were not already on them in the public system
- The Northern Territory also banned puberty blockers in the public system for people under 18
- Health Minister Mark Butler asked the NHMRC to develop national guidelines for the care of trans and gender diverse young people, including priority interim advice on puberty blockers
- The interim advice is called *‘Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18’*
- The full national guidelines on puberty blockers are expected to be available in 2028
- Puberty blockers have been used since the 1980s to treat young children who go through puberty early (precocious puberty)
- The committee suggested puberty blockers could be considered for a young person who had gender incongruence with or without distress, were assessed as suitable for treatment, and had begun puberty
How the outlets covered it
2 outlets reported this story. ABC News published first; The Guardian followed 52 min later.
| Outlet | Published | After first | Headline |
|---|---|---|---|
| ABC News | 16 Nov, 1:23 pm | First | Advice panel gives conditional OK to controversial puberty blockers |
| The Guardian | 16 Nov, 2:15 pm | +52 min | Australia’s national medical research body advises conditional use of puberty blockers for transgender children |
Who reported which facts
| Fact | ABC | Guardian |
|---|---|---|
| The NHMRC interim advice on puberty blockers was released on Monday for public consultation | ✓ | ✓ |
| The NHMRC review included 15 non-randomised studies, most with follow-up of six months to two years | ✓ | ✓ |
| The New Zealand government introduced a ban on new prescriptions of puberty blockers for children with gender dysphoria last year | ✓ | ✓ |
| Queensland became the first state in Australia to restrict access to puberty blockers for children with gender dysphoria who were not already on them in the public system | ✓ | ✓ |
| The Northern Territory also banned puberty blockers in the public system for people under 18 | ✓ | ✓ |
| Health Minister Mark Butler asked the NHMRC to develop national guidelines for the care of trans and gender diverse young people, including priority interim advice on puberty blockers | ✓ | ✓ |
| The interim advice is called *‘Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18’* | ✓ | ✓ |
| The full national guidelines on puberty blockers are expected to be available in 2028 | ✓ | ✓ |
Times are when each outlet published, from its own feed, in Sydney time. Outlets whose feeds don’t give a publish time are listed last. Ticks show which outlets the analysis found reporting each fact. See how this works.
Points of Difference
Details reported by only one source:
- Queensland’s pause on puberty blockers is set to continue until 2031 while awaiting results from the UK’s PATHWAYS trial, which has been delayed due to safety concerns and legal challenges.
- The NHMRC committee found no eligible evidence on the impact of puberty blockers on fertility, fractures, or bone health, though they noted reversible effects on bone health in the short to medium term.
- The ABC reports that the New Zealand High Court recently ruled the country’s puberty blocker ban unlawful, allowing doctors to prescribe them again.
- The Queensland government commissioned an independent review by psychiatrist Ruth Vine, which found limited evidence on fertility impacts and short-to-medium-term bone health effects but noted potential benefits with proper oversight.
- The NHMRC explicitly rejected the ‘wait and see’ model as a form of withholding care, stating it can affect young people’s physical and mental health.
- The guidelines do not require a child to be distressed (gender dysphoria) to be treated for gender incongruence.
- The NHMRC advice aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, Australia’s only existing guidelines for doctors.
- Public consultation on the interim advice is open until 18 January.
Where the reporting differs
Details that conflict, or appear in only some outlets:
- The ABC states Queensland’s ban on puberty blockers was introduced ‘last year,’ while the Guardian says the federal government commissioned the NHMRC review ‘last year’ in response to Queensland’s and Northern Territory’s bans, implying the bans occurred slightly earlier than the ABC’s phrasing suggests.
Source Articles
Advice panel gives conditional OK to controversial puberty blockers
Puberty blockers should remain a clinical option for certain children with gender dysphoria despite limited evidence about their benefits and harms, according to long-awaited national advice.
Australia’s national medical research body advises conditional use of puberty blockers for transgender children
New National Health and Medical Research Council guidelines at odds with public hospital bans in Queensland and NT Get our breaking news email , free app or daily news podcast Australia’s largest medical research organisation has advised puberty blockers are appropriate for the gender-affirming care of children in certain circumstances, after a year-long review of international evidence. The federal government last year commissioned the commonwealth-funded National Health and Medical Research Co
More Technology stories
Nvidia CEO Jensen Huang resigns amid affair and espionage scandal involving alleged Chinese spy Alice Huang
Former NSW MP Rory Amon convicted of raping a 13-year-old boy in 2017
Global Microsoft outage disrupts services, governments, and businesses
Spain’s first general strike in 14 years over housing crisis ahead of November 29 election
Grizzly bear attacks kill mother and daughter in Bella Coola, Canada, reigniting community fears
Australia proposes AI safety reforms after OpenAI Medicare breach
Latest cross-verified stories
Russell Brand convicted of rape and sexual assault, sentenced to over 10 years in prison
Robert Crawford on trial for alleged murder of wife Frances Crawford in Queensland, 2024
Sydney Swans players cleared of charges in Pullman Hotel sexual assault allegations
14-year-old Leihani Zoric wins ISA World Surfing Games, secures Olympic spot for Australia
Rural shooting in Keysbrook orchard leads to murder charge and police operation
Independent MP Helen Haines discharged after car attack, loses both legs
Browse all stories from November 2026 in the archive.